SWK Holdings CorpNASDAQ:SWKH
- LAST PRICE17.0200
- TODAY'S CHANGE (%)-0.2300 (-1.3333%)
- Bid / Lots17.0000/ 3
- Ask / Lots17.4000/ 2
- Open / Previous Close16.7800 / 17.2500
- Day Range
- 52 Week Range
- Volume4,299
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SWKH |
|---|---|---|
| 09:41 ET | 2682 | 17.05 |
| 10:03 ET | 391 | 17 |
| 10:33 ET | 100 | 17.02 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
SWK Holdings Corp | 215.6M | 13.6x | +21.40% |
MCAP Inc | 140.3M | -0.1x | --- |
Silver Spike Investment Corp | 68.8M | 9.2x | --- |
NewtekOne Inc | 273.3M | 5.8x | -0.24% |
Eco Depot Inc | 43.1M | 0.0x | --- |
Princeton Capital Corp | 36.9M | -207.1x | --- |
Company Information
SWK Holdings Corporation is engaged in specialty finance and asset management business. The Company’s segments include Finance Receivables and Pharmaceutical Development. Finance Receivables segment is a healthcare capital provider, which offers customized financing solutions to a range of life science companies, institutions, and inventors. This segment is primarily focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Its Pharmaceutical Development segment operates through its subsidiary Enteris BioPharma, Inc. (Enteris). Enteris is a clinical development and manufacturing organization providing development services to pharmaceutical partners as well as innovative formulation solutions built around its oral drug delivery technologies, the Peptelligence platform.
Contact Information
- Headquarters
- 5956 Sherry Lane, Suite 650DALLAS, TX, United States 75225
- Phone
- 214-217-7253
- Fax
- 972-687-7255
Executives
- Independent Chairman of the Board
- Laurie Dotter
- President, Chief Executive Officer, Interim Chief Financial and Accounting officer
- Joe Staggs
- Director
- Marcus Pennington
- Independent Director
- Jerry Albright
- Independent Director
- Robert Hatcher
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $215.6M |
|---|---|
Revenue (TTM) | $37.8M |
Shares Outstanding | 12.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.33 |
EPS | $1.25 |
Book Value | $22.43 |
P/E Ratio | 13.6x |
Price/Sales (TTM) | 5.7 |
Price/Cash Flow (TTM) | 11.7x |
Operating Margin | 38.80% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
